RBC Capital Reiterates Outperform on Maravai LifeSciences, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara has reiterated an Outperform rating on Maravai LifeSciences (NASDAQ:MRVI) and maintained a $15 price target.
August 16, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Conor McNamara has reiterated an Outperform rating on Maravai LifeSciences and maintained a $15 price target.
The reiteration of an Outperform rating and the maintenance of a $15 price target by RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100